A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: disfigurement (1), damage (326), injury (303), maiming (1)

Rituximab SC (8 weekly) Ver 1

Description
Chemotherapy Protocol LYMPHOMA RITUXIMAB SC (8 weekly) Regimen Lymphoma – Rituximab SC (8 weekly) Indication Maintenance single agent therapy in previously untreated
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-SC-8-weekly-Ver-1.pdf

Rituximab SC (12 weekly) Ver1

Description
Chemotherapy Protocol LYMPHOMA RITUXIMAB SC (12 weekly) Regimen Lymphoma – Rituximab SC (12 weekly) Indication Maintenance single agent therapy in relapsed / refractory
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-SC-12-weekly-Ver1.pdf

CHOP(21)-Cyclophosphamide-Doxorubicin-Prednisolone-Vincristine (21) Ver 1.2

Description
Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-DOXORUBICIN-PREDNISOLONE-VINCRISTINE (21) (CHOP 21) Regimen Lymphoma – CHOP(21)-Cyclophosphamide-Doxorubicin-Prednisolone-Vincristine (21) Indication Non
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/CHOP21-Cyclophosphamide-Doxorubicin-Prednisolone-Vincristine-21-Ver-1.2.pdf

Southampton PTC - Approved chemotherapy regimens 9 June 2020

Description
Appendix B: SOUTHAMPTON PAEDIATRIC ONCOLOGY PRINCIPAL TREATMENT CENTRE List of Approved Chemotherapy Regimens Updated 9th June 2020 Review Date: June 2021
Url
/Media/UHS-website-2019/Docs/PaediatricOncology/Southampton-PTC-Approved-chemotherapy-regimens-9-June-2020.pdf

InP RIVE-Epirubicin-Etoposide-Ifosfamide-Rituximab Ver1.1

Description
Chemotherapy Protocol LYMPHOMA EPIRUBICIN-ETOPOSIDE-IFOSFAMIDE-RITUXIMAB (RIVE) Inpatient Regimen Regimen Lymphoma – InP-RIVE-Epirubicin-Etoposide-Ifosfamide-Rituximab Indication • Non Hodgkin
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-RIVE-Epirubicin-Etoposide-Ifosfamide-Rituximab.pdf

BEACON protocol v8.0 07Mar2023 signed

Description
A randomised phase IIb trial of BE AC v izumab added to Temozolomide O ± Irin tecan for children with N refractory
Url
/Media/UHS-website-2019/Docs/PaediatricOncology/beacon-protocol-v8.0-07mar2023-signed.pdf

NIHR BioBank participant info sheet_v4

Description
PARTICIPANT INFORMATION SHEET The NIHR BioResource Research Tissue Bank Version 4.1 15th March 2023 *If you require this information to
Url
/Media/Southampton-Clinical-Research/Downloads/NIHR-BioBank-participant-info-sheet-v4.pdf

NIHR_RTB_PIS-ICF_v4.1_15Mar2023Localised

Description
PARTICIPANT INFORMATION SHEET The NIHR BioResource Research Tissue Bank Version 4.1 15th March 2023 *If you require this information to
Url
/Media/Southampton-Clinical-Research/Downloads/NIHR-RTB-PIS-ICF-v4.1-15Mar2023Localised.pdf

NIHR_RTB_PIS-ICF_v4.1_15Mar2023Localised

Description
2 PARTICIPANT INFORMATION SHEET The NIHR BioResource Research Tissue Bank Version 4.1 15th March 2023 *If you require this information
Url
/Media/Southampton-Clinical-Research/Downloads/NIHR-RTB-PIS-ICF-v4.1-15Mar2023Localised.docx

Papers CoG 16.07.2025

Description
Date Time Location Chair Agenda Council of Governors 16/07/2025 14:00 - 15:30 Conference Room, Heartbeat/Microsoft Teams Jenni
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Governors/Papers-CoG-16.07.2025.pdf
51 to 60 of 66
Previous … 3 4 5 6 7 Next